Tags

Type your tag names separated by a space and hit enter

Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
Ren Fail 2009; 31(3):221-8RF

Abstract

Objective.

Patients with chronic renal failure (CRF) have an increased risk of death from cardiovascular diseases. The metabolic syndrome is a common risk factor for cardiovascular diseases. In the present study, it was aimed to evaluate the frequency of metabolic syndrome using the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) definitions in patients with end-stage CRF undergoing hemodialysis (HD). Materials and Methods. A total of 222 cases undergoing HD were enrolled in the study. After obtaining medical history and physical examination, blood samples were collected from each patient for the measurements of fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.

Results.

Among HD patients evaluated according to both IDF and NCEP-ATP III definitions, the diagnosis of metabolic syndrome was confirmed by IDF in 56.5% of those fulfilling the criteria for NCEP-ATP III. Similarly, 86% of the undiagnosed patients according to NCEP-ATP III were confirmed by IDF definitions. The sensitivity and positive predictive value of NCEP-ATP III for metabolic syndrome were 81.25% and 64.8%, respectively. The area under the Receiver Operating Characteristic (ROC) curve for NECP-ATP III and IDF was 0.730. False-positive rate and probability ratio for NECP-ATP III were 0.352 and 2.49, respectively. In other words, among the patients who were diagnosed with metabolic syndrome according to NCEP-ATP III definitions, the proportion of subjects whose diagnosis was confirmed by IDF definitions was 2.49-fold higher than those with unconfirmed diagnosis.

Conclusion.

It is logical to evaluate patients with CRF for metabolic syndrome and cardiovascular risk factors at the time of diagnosis and regularly thereafter due to the high ratio of metabolic syndrome in this population.

Authors+Show Affiliations

Department of Internal Medicine, Mustafa Kemal University Faculty of Medicine, Hatay, Turkey. edipucar@mail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19288328

Citation

Ucar, Edip, et al. "Frequency of Metabolic Syndrome Among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions." Renal Failure, vol. 31, no. 3, 2009, pp. 221-8.
Ucar E, Huzmeli C, Guven O, et al. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Ren Fail. 2009;31(3):221-8.
Ucar, E., Huzmeli, C., Guven, O., Savas, N., Gullu, M., Asilyoruk, S., ... Kuvandik, G. (2009). Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. Renal Failure, 31(3), pp. 221-8. doi:10.1080/08860220802669883.
Ucar E, et al. Frequency of Metabolic Syndrome Among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions. Ren Fail. 2009;31(3):221-8. PubMed PMID: 19288328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions. AU - Ucar,Edip, AU - Huzmeli,Can, AU - Guven,Oguz, AU - Savas,Nazan, AU - Gullu,Murat, AU - Asilyoruk,Sema, AU - Kuvandik,Ceren, AU - Temizkan,Aysegul, AU - Kuvandik,Guven, PY - 2009/3/17/entrez PY - 2009/3/17/pubmed PY - 2009/5/19/medline SP - 221 EP - 8 JF - Renal failure JO - Ren Fail VL - 31 IS - 3 N2 - Objective. Patients with chronic renal failure (CRF) have an increased risk of death from cardiovascular diseases. The metabolic syndrome is a common risk factor for cardiovascular diseases. In the present study, it was aimed to evaluate the frequency of metabolic syndrome using the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) definitions in patients with end-stage CRF undergoing hemodialysis (HD). Materials and Methods. A total of 222 cases undergoing HD were enrolled in the study. After obtaining medical history and physical examination, blood samples were collected from each patient for the measurements of fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Results. Among HD patients evaluated according to both IDF and NCEP-ATP III definitions, the diagnosis of metabolic syndrome was confirmed by IDF in 56.5% of those fulfilling the criteria for NCEP-ATP III. Similarly, 86% of the undiagnosed patients according to NCEP-ATP III were confirmed by IDF definitions. The sensitivity and positive predictive value of NCEP-ATP III for metabolic syndrome were 81.25% and 64.8%, respectively. The area under the Receiver Operating Characteristic (ROC) curve for NECP-ATP III and IDF was 0.730. False-positive rate and probability ratio for NECP-ATP III were 0.352 and 2.49, respectively. In other words, among the patients who were diagnosed with metabolic syndrome according to NCEP-ATP III definitions, the proportion of subjects whose diagnosis was confirmed by IDF definitions was 2.49-fold higher than those with unconfirmed diagnosis. Conclusion. It is logical to evaluate patients with CRF for metabolic syndrome and cardiovascular risk factors at the time of diagnosis and regularly thereafter due to the high ratio of metabolic syndrome in this population. SN - 1525-6049 UR - https://www.unboundmedicine.com/medline/citation/19288328/Frequency_of_metabolic_syndrome_among_hemodialysis_patients_according_to_NCEP_ATP_III_and_IDF_definitions_ L2 - http://www.tandfonline.com/doi/full/10.1080/08860220802669883 DB - PRIME DP - Unbound Medicine ER -